SCHEMBL1562285

SCHEMBL1562285

O=C(O)c1cc(OCc2ccccc2)cc2ccc(=O)oc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.56
CA9 Q16790 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
NPC1 O15118 2/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA3 P07451 1/20 0.56
MAOA P21397 1/20 0.56
CA4 P22748 1/20 0.56
CA6 P23280 1/20 0.56
CA7 P43166 1/20 0.56
MTNR1A P48039 1/20 0.56
CA14 Q9ULX7 1/20 0.56
SLC16A3 O15427 1/20 0.56
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
MCL1 Q07820 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1561280 0.88 CA9 (0.53) MAOBCA9MEN1KMT2ANPC1
SCHEMBL1562291 0.83 MAOB (0.60) MAOBCA9MEN1KMT2ANPC1
SCHEMBL23796860 0.77 MEN1 (0.65) MAOBMEN1KMT2ASLC16A3KDM4E
SCHEMBL27862583 0.75 MEN1 (0.58) MAOBMEN1KMT2ASLC16A3KDM4E
SCHEMBL3592957 0.74 MAOB (0.81) MAOBCA9MEN1KMT2ANPC1
SCHEMBL27489408 0.73 MEN1 (0.63) MAOBMEN1KMT2ASLC16A3MCL1
7-Benzyloxycoumarin SCHEMBL29365449 0.72 MAOB (1.00) MAOBCA9MEN1KMT2ANPC1
7-Benzyloxycoumarin SCHEMBL3901170 0.72 MAOB (1.00) MAOBCA9MEN1KMT2ANPC1
SCHEMBL343794 0.72 MCL1 (0.78) MAOBMEN1KMT2AMAOASLC16A3
SCHEMBL4992573 0.72 MEN1 (0.47) MAOBMEN1KMT2ANPC1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805160-B1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS LILLY CO ELI (US) 2011-04-06 EP disclosed
US-7354951-B2 Substituted benzopyrans as selective estrogen receptor-beta agonists ELI LILLY AND COMPANY (US) 2008-04-08 US disclosed
US-20080064742-A1 Substituted Benzopyrans as Selective Estrogen Receptor-Beta Agonists ELI LILLY AND COMPANY 2008-03-13 US disclosed
EP-1805160-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2007-07-11 EP disclosed
WO-2006044176-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064742-A1 Substituted Benzopyrans as Selective Estrogen Receptor-Beta Agonists ESR2, GPER1, ESR1 MAOB 1276/4885CA9 3318/4885MEN1 2888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.